Investor FAQs

What is the focus of Travere Therapeutics' business?

Travere Therapeutics is a biopharmaceutical company with a global team dedicated to working with the rare disease community to identify, develop and deliver life-changing therapies. The Company’s development efforts are led by sparsentan, a product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) – rare kidney disorders that often lead to end-stage kidney disease. The company is also advancing TVT-058 for the treatment of classical homocystinuria, a genetic metabolic disorder that can cause life-threatening thrombotic events. Travere Therapeutics’ early research efforts include partnering with leaders in patient advocacy and government research to identify potential therapeutics for NGLY1 deficiency and Alagille syndrome, conditions with no approved treatment options. The Company also delivers four FDA-approved therapies, Chenodal®, Cholbam®, Thiola® and Thiola EC®, and is committed to ensuring broad access, educational and financial support for patients. For more information, visit travere.com.

When was Travere Therapeutics founded?

What is Travere Therapeutics' fiscal year?

Where is Travere Therapeutics’ stock traded, and what is the ticker symbol?

Where is Travere Therapeutics incorporated?

What is your stock's CUSIP number?

Where is Travere Therapeutics' headquarters located?

Does Travere Therapeutics pay a dividend? Do you have a Dividend Reinvestment Plan?

Who is Travere Therapeutics' transfer agent?

Who do I contact about replacement of stock certificates?

I'm a shareholder, whom should I notify of a change in address?

Who is Travere Therapeutics’ auditor?

How can I get a copy of your Annual report or any other investor materials (i.e., Investor Relations kit, 10-K)?

How can I contact Travere Therapeutics or direct more questions?